4.8 Review

Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading?

期刊

CANCER CELL
卷 36, 期 1, 页码 6-16

出版社

CELL PRESS
DOI: 10.1016/j.ccell.2019.06.006

关键词

-

资金

  1. FEDER funds through the Operational Programme for Competitiveness Factors-COMPETE [POCI-01-0145-FEDER-016585, POCI-01-0145-FEDER-007274, POCI-01-0145-FEDER-028489]
  2. National Funds through the Foundation for Science and Technology (FCT) [PTDC/BBB-EBI/0567/2014, UID/BIM/04293/2013, CEECIND/02760/2017, NORTE-01-0145-FEDER-000029]
  3. Norte Portugal Regional Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF)
  4. European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant [748880]
  5. Marie Curie Actions (MSCA) [748880] Funding Source: Marie Curie Actions (MSCA)
  6. Fundação para a Ciência e a Tecnologia [PTDC/BBB-EBI/0567/2014] Funding Source: FCT

向作者/读者索取更多资源

This review provides insights on the impact of glycosylation in cancer biology and its influence in the current approaches of targeted cancer therapies in the clinical setting. The roles of glycosylation in cancer signaling, tumor progression, and metastasis are reviewed as well as glycans and glycan-binding proteins in tumor immunomodulation. Moreover, the latest reports on glycans influencing targeted therapeutic approaches in cancer are summarized. Finally, we discuss the future challenges of the field, outlining potential applications of glycan-based biomarkers for patient stratification and strategies for improving personalized cancer treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据